Compare FNLC & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNLC | EOLS |
|---|---|---|
| Founded | 1864 | 2012 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.9M | 304.0M |
| IPO Year | 1995 | 2018 |
| Metric | FNLC | EOLS |
|---|---|---|
| Price | $29.50 | $4.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.40 |
| AVG Volume (30 Days) | 15.8K | ★ 925.7K |
| Earning Date | 04-22-2026 | 03-29-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ 2.16 | N/A |
| Revenue | N/A | ★ $266,274,000.00 |
| Revenue This Year | N/A | $13.57 |
| Revenue Next Year | N/A | $11.39 |
| P/E Ratio | $13.40 | ★ N/A |
| Revenue Growth | N/A | ★ 31.76 |
| 52 Week Low | $22.11 | $4.09 |
| 52 Week High | $30.33 | $14.93 |
| Indicator | FNLC | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 34.32 |
| Support Level | $28.88 | $4.25 |
| Resistance Level | $29.71 | $4.50 |
| Average True Range (ATR) | 0.72 | 0.26 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 64.29 | 26.00 |
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.